Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study on the"Fuzheng"Therapy Promoted Immune Reconstitution to Improve the Survival of Early-stage Lung Cancer After Surgical Operation

NCT02603003 is registered in ClinicalTrials.gov with Shanghai University of Traditional Chinese Medicine as lead sponsor.

NCT NCT02603003
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02603003 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study on the"Fuzheng"Therapy Promoted Immune Reconstitution to Improve the Survival of Early-stage Lung Cancer After Surgical Operation
Lead sponsor
Shanghai University of Traditional Chinese Medicine
Phase
Phase 1
Overall status
Completed
Start date
June 30, 2015
Completion date
September 1, 2019
Enrollment
218 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer(nsclc)